Akoya biosciences expands biopharma service portfolio with new adc breast cancer assay and real-world io60 insights at aacr 2025

Marlborough, mass., april 24, 2025 (globe newswire) -- akoya biosciences, inc. (nasdaq: akya), the spatial biology company®, today announced the availability of a new assay designed to advance antibody-drug conjugate (adc) development in breast cancer.

AKYA Ratings Summary

AKYA Quant Ranking